Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Boston Scientific Corporation    BSX

BOSTON SCIENTIFIC CORPORATION

(BSX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Boston Scientific : Description Statement of Changes in Beneficial Ownership

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 05:57pm EDT

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or

Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person *

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Sorenson John Bradley

BOSTON SCIENTIFIC CORP [ BSX ]

_____ Director

_____ 10% Owner

(Last)

(First)

(Middle)

3. Date of Earliest Transaction (MM/DD/YYYY)

__ X __ Officer (give title below)

_____ Other (specify below)

300 BOSTON SCIENTIFIC WAY

8/13/2019

SVP, Manuf & Sup Chn

(Street)

4. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

MARLBOROUGH, MA 01752-1234

_ X _ Form filed by One Reporting Person

(City)

(State)

(Zip)

___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security

2. Trans. Date

2A. Deemed

3. Trans. Code

4. Securities Acquired (A) or

5. Amount of Securities Beneficially Owned

6.

7. Nature

(Instr. 3)

Execution

(Instr. 8)

Disposed of (D)

Following Reported Transaction(s)

Ownership

of Indirect

Date, if any

(Instr. 3, 4 and 5)

(Instr. 3 and 4)

Form:

Beneficial

Direct (D)

Ownership

or Indirect

(Instr. 4)

(A) or

(I) (Instr.

Code

V

Amount

(D)

Price

4)

Common Stock

8/13/2019

S

6000.0000

D

$42.7929

42385.0000

D

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate

2.

3. Trans.

3A. Deemed

4. Trans. Code

5. Number of

6. Date Exercisable and

7. Title and Amount of

8. Price of

9. Number of

10.

11. Nature

Security

Conversion

Date

Execution

(Instr. 8)

Derivative Securities

Expiration Date

Securities Underlying

Derivative

derivative

Ownership

of Indirect

(Instr. 3)

or Exercise

Date, if any

Acquired (A) or

Derivative Security

Security

Securities

Form of

Beneficial

Price of

Disposed of (D)

(Instr. 3 and 4)

(Instr. 5)

Beneficially

Derivative

Ownership

Derivative

(Instr. 3, 4 and 5)

Owned

Security:

(Instr. 4)

Security

Following

Direct (D)

Date

Expiration

Title

Amount or Number of

Reported

or Indirect

Code

V

(A)

(D)

Exercisable

Date

Shares

Transaction(s)

(I) (Instr.

(Instr. 4)

4)

Explanation of Responses:

Reporting Owners

Reporting Owner Name / Address

Relationships

Director

10% Owner

Officer

Other

Sorenson John Bradley

300 BOSTON SCIENTIFIC WAY

SVP, Manuf & Sup Chn

MARLBOROUGH, MA 01752-1234

Signatures

/s/ Scott G. Hodgdon, Attorney-in-Fact

8/14/2019

**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

  • If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  • Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Disclaimer

Boston Scientific Corporation published this content on 14 August 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 August 2019 21:56:06 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BOSTON SCIENTIFIC CORPORAT
09:31aBOSTON SCIENTIFIC : to Participate in the 2019 Wells Fargo Securities Healthcare..
PR
08/19BOSTON SCIENTIFIC : Announces FDA Approval Of ImageReady™ MRI For Vercise ..
PR
08/19BOSTON SCIENTIFIC : Description Statement of Changes in Beneficial Ownership
PU
08/19BOSTON SCIENTIFIC : Description Current report filing
PU
08/19BOSTON SCIENTIFIC CORP : Creation of a Direct Financial Obligation or an Obligat..
AQ
08/15BOSTON SCIENTIFIC : Description Current report filing
PU
08/15BOSTON SCIENTIFIC CORP : Other Events, Financial Statements and Exhibits (form 8..
AQ
08/14BOSTON SCIENTIFIC : Description Statement of Changes in Beneficial Ownership
PU
08/07BOSTON SCIENTIFIC : Responds to the FDA's Guidance on Use of Peripheral Paclitax..
PU
08/07BOSTON SCIENTIFIC CORP : Other Events, Financial Statements and Exhibits (form 8..
AQ
More news
Financials (USD)
Sales 2019 10 670 M
EBIT 2019 2 784 M
Net income 2019 1 409 M
Debt 2019 4 749 M
Yield 2019 -
P/E ratio 2019 43,7x
P/E ratio 2020 31,3x
EV / Sales2019 6,03x
EV / Sales2020 5,49x
Capitalization 59 536 M
Chart BOSTON SCIENTIFIC CORPORATION
Duration : Period :
Boston Scientific Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BOSTON SCIENTIFIC CORPORAT
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Average target price 47,08  $
Last Close Price 42,74  $
Spread / Highest target 24,0%
Spread / Average Target 10,2%
Spread / Lowest Target -36,8%
EPS Revisions
Managers
NameTitle
Michael F. Mahoney Chairman, President & Chief Executive Officer
John Bradley Sorenson Senior Vice President-Manufacturing & Supply Chain
Edward Mackey Executive Vice President-Operations
Daniel J. Brennan Chief Financial Officer & Executive Vice President
Ian T. Meredith Global Chief Medical Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
BOSTON SCIENTIFIC CORPORATION19.27%59 536
THERMO FISHER SCIENTIFIC24.90%111 941
DANAHER CORPORATION37.42%101 658
INTUITIVE SURGICAL3.46%57 108
EDWARDS LIFESCIENCES CORPORATION43.20%46 273
ILLUMINA, INC.-4.59%42 432